跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAN 296
首页
药物
CAN 296
CAN 296
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Human miR-296-5p antisense nucleic acid and application thereof
申请人: SUZHOU GENEPHARMA CO LTD
优先权: 2009
CN
Application of miR-296-3p to preparation of kit for diagnosing prostate cancer generation or migration
申请人: SHANGHAI JIAOTONG UNIV SCHOOL MEDICINE
优先权: 2012
CN
Antibody MesoR11 targeting human mesothelin, CAR-T cell based on antibody and application
申请人: SUZHOU TONGQIAN MEDICAL TECH CO LTD
优先权: 2024
CN
Rice WRKY70 transcription factor and application thereof in improving stress tolerance of plants
申请人: UNIV HUNAN AGRICULTURAL
优先权: 2025
CN
Application of ginkgetin in preparation of GRP78 protein inhibitor
申请人: SHANGHAI GENERAL HOSPITAL
优先权: 2025
CN
RNA BIOMARKERS FOR USE IN TREATING, DIAGNOSING, AND MONITORING COLORECTAL CANCER AND COLORECTAL ADENOMA
申请人: HOPE CITY
优先权: 2024
WO
Antifungal combination use
申请人: FUJISAWA PHARMACEUTICAL CO
优先权: 1999
US
3 件公开
Artificial active peptide for promoting cartilage repair as well as preparation method and application of artificial active peptide
申请人: LI HONGFANG
优先权: 2023
CN
药物
反馈